


Tazarotenic acid-d₆

Cat. No.:	HY-101108S
CAS No.:	1794760-38-5
Molecular Formula:	C ₁₉ H ₁₁ D ₆ NO ₂ S
Molecular Weight:	329.45
Target:	Drug Metabolite; Isotope-Labeled Compounds
Pathway:	Metabolic Enzyme/Protease; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Tazarotenic acid-d ₆ is deuterium labeled Tazarotenic acid. Tazarotenic acid is the metabolite of Tazarotene. Tazarotenic acid binding to retinoic acid receptors (RARs) is the probable molecular target of retinoid action. Tazarotenic acid has the potential for the research of warty dyskeratoma ^{[1][2][3]} .
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Abramovits W, et al. Treatment of warty dyskeratoma with tazarotenic acid. *J Am Acad Dermatol.* 2002;46(2 Suppl Case Reports):S4.
- [2]. Chandraratna RA. Tazarotene--first of a new generation of receptor-selective retinoids. *Br J Dermatol.* 1996;135 Suppl 49:18-25.
- [3]. Hsyu PH, et al. Pharmacokinetics of a novel retinoid AGN 190168 and its metabolite AGN 190299 after intravenous administration of AGN 190168 to rats. *Biopharm Drug Dispos.* 1994;15(5):347-357.
- [4]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA